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Abstract
Background: Millions of people have been infected with the novel Coronavirus 2019, creating a
global pandemic. Despite the high mortality rate of this viral infection, millions of people have
recovered, and are now presenting for surgical procedures with a history of COVID-19 infection.
Residual effects of COVID-19 infection have been observed for several after diagnosis and are
referred to as post COVID-19 syndrome. Post COVID-19 sequela can alter multisystem
physiological processes that may alter anesthetic care throughout the perioperative period.
Objectives: The purpose of this quality improvement project is to improve anesthesia provider
knowledge on the management of patients who have post COVID-19 syndrome.
Methods: The primary methodology of the proposed quality improvement project is to
administer an educational intervention to anesthesia providers which discusses the management
of patients undergoing elective surgery and have a history of COVID-19 infection. Pre- and postassessment surveys will be used to measure the effectiveness of the educational intervention.
Results: Overall, there was an improvement in anesthesia provider knowledge following the
educational intervention. Participants also answered they would “always” or “often” consider
additional pre-operative testing compared to “sometimes” prior to the educational intervention.
Keywords: Post COVID-19 syndrome, Post COVID-19 Sequela, Coronavirus 2019, Anesthesia,
Anesthesia Implications
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Problem Identification
The novel coronavirus disease 2019 (COVID-19) has been a leading cause of death
worldwide.1 Clinical symptoms of COVID-19 vary from asymptomatic to multiorgan systems
affected including respiratory failure, cardiomyopathy, renal failure, liver function abnormalities,
thromboembolic disease, and neurologic manifestations.2 Despite the severity of the disease and
high mortality rate, several million people have recovered from COVID-19 but may have
residual side effects from the viral disease. This is now referred to as post-COVID syndrome,
defined as recovered from the viral infection, but continued symptoms such as fatigue,
inflammation, chest tightness, dyspnea, and headaches several months after diagnosis.
At the peak of the pandemic, several healthcare systems reduced the number of elective
surgeries performed as a means to limit patient exposure to the virus, conserve personal
protective equipment, and utilize staff elsewhere within the hospital.3 As healthcare systems
resume elective procedures, patients are presenting for surgical services with post-COVID
syndrome. As anesthesia providers continue to learn more about the virus and how to manage the
care of acute COVID-19 infection, little is known about the anesthetic implications of patients
who have recovered from COVID-19. The goal of this project is to improve anesthesia
providers’ knowledge of anesthetic implications throughout the perioperative period for patients
previously diagnosed with COVID-19.
Background
Anesthesia providers perform a wide variety of anesthetic techniques such as general,
monitored anesthesia care (MAC), regional, and local anesthesia depending on what is
appropriate for the patient and type of surgical procedure. Additionally, several considerations
are incorporated into the anesthetic care plan as each patient is unique with varying
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comorbidities altering their anesthetic management. For example, regional anesthesia is preferred
over general anesthesia for patients with chronic obstructive pulmonary disease (COPD) as this
method minimizes respiratory complications such as barotrauma or bronchospasm.4
Furthermore, if a patient with COPD is under general anesthesia, the anesthesia provider should
deliver ventilation at a low respiratory rate to allow for sufficient expiratory time to minimize
auto-peep or air trapping. Conversely, the management of a patient with acute respiratory
distress syndrome (ARDS) requires general anesthesia, low tidal volumes, a higher respiratory
rate, and the use of positive end-expiratory pressure (PEEP). These are only two brief examples
of how the management of anesthesia is altered depending on the patient’s preexisting
comorbidities.
The COVID-19 pandemic has continued to evolve, several governmental agencies and
professional organizations have developed protocols to assist in the management of care for
patients infected with COVID-19. The American Association of Nurse Anesthesiology (AANA)
provides guidelines for elective surgery of patients with diagnosed with COVID-19. These
guidelines include preoperative COVID-19 testing, patient visitor limitation, operating room
processing, and aftercare of staff members exposed.5 Furthermore, the National Institute of
Health has developed several treatment guidelines to provide clinicians the most current updates
in treatment regimens.6 In respect to anesthesia management, the American Society of
Anesthesiologists (ASA) and the Anesthesia Patient Safety Foundation (APSF) have developed a
joint statement for elective surgery and anesthesia for patients after COVID-19 infection.7
Within this statement, the ASA and APSF provide guidelines for preoperative testing and the
timing of elective procedures after diagnosis. The organizations also recognize residual
symptoms after COVID-19 infection can exist for more than 60 days after diagnosis, requiring a
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thorough preoperative evaluation focusing on the cardiopulmonary system. However, there are
no recommendations for the management of anesthesia.
Scope of the Problem
On March 11, 2020, the World Health Organization (WHO) declared the COVID-19
outbreak a global pandemic.8 Since then, millions of deaths have occurred worldwide. Among
those diagnosed with COVID-19, research identified post-COVID syndrome to exist in 50.9%
(n=277) of those who have recovered.9 Furthermore, it has been estimated that 15% to 20% of
the patients requiring surgery have previously been infected with COVID-19.10 Given the large
scale of patients presenting for surgical services with post-COVID syndrome, it is imperative
that appropriate measures are taken throughout the perioperative period for the best possible
patient outcome.
Consequences of the Problem
After initially restricting the number of elective and non-urgent surgeries performed
during the COVID-19 pandemic, several healthcare facilities have resumed surgical procedures.
Studies have indicated patients experience significantly higher morbidity and mortality rate after
surgical procedures while positive for COVID-19, irrespective of comorbidities.11 However,
limited data exist on patients with post COVID-19 syndrome as it relates to patient outcomes.
The COVID Surg-Cancer study reported patients previously infected with COVID-19 were
associated with an increased incidence of postoperative pulmonary complications compared to
those who had not been diagnosed with COVID-19, 10.7% and 3.6% respectively.12 Zhao et al.
described pulmonary function tests (PFTs) abnormalities in 25.45% of patients 3 months after
discharge from COVID-19 infection.13 Among PFTs, there was an observed decrease in total
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lung capacity (TLC), Forced expiratory capacity at the first second of exhalation (FEV1), forced
vital capacity (FVC), and diffusion capacity of the lung for carbon monoxide (DLCO). These
studies suggest impaired lung function months after infection.
Preoperative abnormalities in PFTs have been reported as strong indicators for
postoperative complications. Reddi et al. associated decreased DLCO and FVC with prolonged
postoperative ventilation and length of hospital stay in patients undergoing elective cardiac
surgery.14 Although evidence is limited, current research suggests patients are at an increased
risk of postoperative complications when previously infected with COVID-19. Therefore,
anesthesia providers must understand the clinical implications to care for patients who have
previously been infected with COVID-19.
Knowledge Gaps
Several major medical events warrant a designated period for recovery prior to elective or
non-emergent procedures. Evidence-based research suggests a minimum time of 8 weeks after
myocardial infarction, 1 month after an upper respiratory infection, and 3-9 months after a
cerebral vascular accident to allow for best patient outcomes after surgery.2 In the same way,
COVID-19 infection could be classified as a major medical event. However, a safe time for
recovery before elective procedures has yet to be determined. The ASA and APSF joint
statement guidelines on elective surgery timing after COVID-19 infection are broad and
generalized. The statement recommends a lapsed time of 4, 6, 8, and 12 weeks for asymptomatic
patients, symptomatic but required no hospitalization, symptomatic and hospitalized, or admitted
to intensive care unit respectively.7 There is limited data on the anesthetic management of
patients who were previously infected and now exhibit signs of post COVID-19 syndrome.
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To safely administer anesthesia, providers must first understand a patient’s underlying
medical comorbidities and how the pathophysiology may alter the anesthetic plan of care. While
the knowledge of the pathophysiology of post COVID-19 syndrome is sparse, perioperative
anesthetic management of patients previously infected with COVID-19 has been extrapolated
from other medical conditions which have similar symptoms.15 Anesthetic considerations of
neuromuscular disorders such as cautious use of opioids and neuromuscular blockers may be
indicated when post COVID-19 syndrome patients exhibit neuromuscular deconditioning
symptoms. In COVID-19 patients, the cardiopulmonary system should be thoroughly evaluated
with a low threshold for preoperative electrocardiogram, transthoracic echocardiography,
pulmonary function tests, or chest radiographs. Other preoperative assessments should include
considerations of renal and hematologic systems such as lab values, avoidance of nephrotoxic
medication, and thromboprophylaxis.
These anesthetic considerations for post COVID-19 syndrome are grounded on available
evidence and information from other post-viral syndromes. As the COVID-19 pandemic
continues, millions of people remain at risk for long-term sequela of post COVID-19 syndrome.
Anesthesia providers need to carefully assess individual patients who are de-conditioned after
COVID-19 infection since specific anesthetic implications for this patient population are not yet
well defined.
Proposal Solution
Various quality improvement projects have been initiated in response to the COVID-19
pandemic to keep healthcare providers informed and improve patient outcomes. For example, the
Cleveland Clinic educated healthcare workers by increasing the frequency of team meetings,
formed quality committees to deliver education on specific clinical skills, and created various
Page 10 of 71
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protocols for clinical scenarios such as patient transport, airway management, and medication
use.16 Several quality improvement efforts were developed to improve patient outcomes of
acutely infected COVID-19 patients. Little information is available to educate anesthesia
providers on the implications of patients with post COVID-19 syndrome. To improve
perioperative patient outcomes, anesthesia providers should be educated on post COVID-19
syndrome and associated anesthetic implications.
Objective
This literature review first summarizes relevant research describing symptoms of post
COVID-19 syndrome sequela. The review provides evidence for anesthetic implications
throughout the perioperative period for patients who have recovered from COVID-19. The last
objective is to describe how these symptoms may alter an anesthesia provider’s plan of care.
PICO Question
Population (P): Anesthesia providers
Intervention (I): Educational presentation on anesthetic management for patients with post
COVID-19 syndrome
Comparison (C): No education
Outcomes (O): Improved provider knowledge of anesthetic management for patients who have
post COVID-19 syndrome
Methodology
A comprehensive literature search was performed using The Cumulative Index to
Nursing and Allied Health Literature (CINAHL), Google Scholar, and PubMed databases.
Searches with the following keywords were included in the search strategies using appropriate
Boolean operators and search symbols: “post covid syndrome” OR “post covid-19 syndrome”
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OR “post covid-19” OR “after covid-19” OR “post coronavirus” OR “after coronavirus” AND
“symptoms” OR “anesthesia” OR “anesthesia management.” The search results were restricted
to full text, English language, peer-reviewed, and within the time from 2019-2021. Database
sources used for the research were accessed via Florida International University (FIU) library
services.
Preliminary search results yielded 146 articles total, CINAHL, Google Scholar, and
PubMed databases representing 109, 89, and 61 articles respectively. Articles were excluded if
they did not relate to the PICO question. Articles describing care of the patient with an acute
COVID-19 infection were omitted because this literature review is examining the anesthesia
implications of post-COVID-19 infection. Other articles removed included those that described
the management of resuming elective surgery during the pandemic and protocols to minimize the
spread of infection among staff. After exclusions, 30 articles remained and were analyzed. Only
7 articles described the anesthetic management or perioperative care of patients, whereas the
remaining 23 highlighted symptoms and physiological changes of post COVID-19 syndrome.
Review of Literature
The articles selected for this literature review described several sequelae present among
patients with post COVID-19 syndrome. While some articles examined multiorgan system
symptoms, other articles described only specific systems such as cardiovascular system
compromise. Eight articles were used to describe the pulmonary system, 6 for cardiovascular, 8
for neurological, 2 for renal, 4 for gastrointestinal and liver, 3 for endocrine, 5 for mental health,
and 7 for anesthetic implications. Further detail describing an overview of the literature results
are listed in Table 1.
Pulmonary System
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Pulmonary compromise was among the most prevalent sequela among patients with post
COVID-19 syndrome. Frija-Masson and colleagues reported 51.9% of patients experienced
residual lung function abnormalities 30 days after COVID-19 infection.17 These patients
demonstrated a mix of restrictive and low diffusion patterns. Median interquartile ranges of
FVC, TLC, DLCO, FEV1/FVC were 93%, 91.5%, 80%, and 81% of predicted values
respectively. Zhao et al. conducted a multicenter retrospective cohort study examining the
pulmonary function of COVID-19 survivors 3 months after discharge from the hospital.13
Spirometry abnormalities including decreased TLC, FEV1, FVC, and DLCO were observed in
25.45% of patients. Similarly, Huang et al detected abnormal pulmonary function tests (PFTs) in
patients 6 months after diagnosis.18 Among the 349 participants, DLCO impairment was the
most evident, with decreases in 22% of patients who required no supplemental oxygen, 29% who
required supplemental oxygen, and 56% who required more invasive support such as noninvasive or mechanical ventilation during hospital admission. Other spirometry studies indicated
6 months after diagnosis of COVID-19, patients still exhibited decreases in FEV1 < 80% of
predicted (6%), FVC < 80% of predicted (4%), FEV1/FVC < 70% of predicted (6%), TLC <
80% of predicted (16%), FRC < 80% of predicted (7%), and RV < 80% of predicted (25%).
Raman et al observed equal spirometry changes 2-3 months after COVID-19 with significant
decreases in FEV1, FVC, and higher FEV1/FVC ratio than the control group.19 Additionally,
Moreno-Perez and colleagues described spirometry abnormalities in 9.3% of patients 72-85 days
after disease onset.9 Majority of the spirometry measurements in this study were found to be an
obstructive pattern, which improved after 16-18 weeks.
Other pulmonary findings of post COVID-19 syndrome have been evidenced on
radiological imaging or computed tomography (CT) scans. Zhao et al. reported 70.9% of patients
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showed radiological abnormalities 3 months after discharge.13 Pulmonary CT changes such as
ground-glass opacities, interstitial thickening, and crazy paving involved bilateral, right lower
lobe, left lower lobe, and left upper lobe in 23%, 41%, 22%, and 20% of patients respectively.
Ding and associates analyzed CT scans of 112 COVID-19 positive patients at 6 different time
intervals to monitor the progression of infection.20 Among these patients, the most common CT
findings included ground-glass opacifications, crazy paving, consolidation, and linear opacities.
These manifestations of pulmonary imaging were observed in 98.1% of patients 28 days after
symptom onset. Additional CT findings after 28 days from symptoms included air bronchogram,
bronchiectasis, and pleural effusion, occurring 24.5%, 45.2%, and 15.1% respectively.
Consistent with these CT results, Huang et al reported ground-glass opacity and irregular lines as
the most common features of CT imaging 6 months after discharge from COVID-19 infection.18
Interestingly, ground-glass opacities were more common in patients who required supplemental
oxygen during hospital admission (48%) when compared to patients who did not require oxygen
(41%) with an odds ratio of 1.19. Patients who required more invasive ventilation support
during hospital admission displayed ground-glass opacities more frequently (45%) when
compared to patients who did not require supplemental oxygen, however, there was no
significant difference between these two groups with an odds ratio of 0.93.
The use of chest X-rays were also used to assess the pulmonary status of patients after
COVID-19 infection. Taylor and colleagues performed chest X-rays on 545 COVID-19
survivors 12 weeks after discharge.21 Patients were categorized as “high-risk” if during hospital
admission they required intensive care, received high flow nasal oxygen, continuous positive
airway pressure (CPAP), mechanical, or non-invasive ventilation. All other patients in the study
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were categorized as “low-risk.” Resolution of COVID-19 associated lung changes were found in
69% of high-risk patients and 83% of low-risk patients.
Despite the apparent resolution of radiologic changes in the majority of patients after
COVID-19, D’Cruz et al argue that chest radiography is a poor indicator of pulmonary function
in COVID-19 survivors.22 Implementing the Radiographic Assessment of Lung Edema (RALE)
scoring system, researchers found 87% of patients exhibited resolution of COVID-19, defined by
a RALE score less than 5, on chest radiography 2 months after severe COVID-19 infection.
However, 75% of these same patients demonstrated CT abnormalities consistent with COVID
related interstitial lung disease. Furthermore, only 21% of patients with abnormal CT results also
had abnormal chest radiographs. For this reason, the researchers suggest chest radiographs 2
months after COVID-19 infection were not a reliable indicator of physiological status. Only
Raman et al. examined magnetic resonance imaging (MRI) 2-3 months after infection and
observed parenchymal abnormalities in 60% of patients.19
Cardiovascular System
Acute COVID-19 infection has been shown to compromise the cardiovascular system as
the disease can cause myocarditis, reduced systolic function, myocardial injury, or ischemia.23
Studies have indicated chest pain (5%) and palpitations (9%) exist 6 months after diagnosis.18
Huang et al performed cardiac magnetic resonance (CMR) on 26 patients an average of 47 days
after symptoms.24 Patients reported precordial chest pain, chest distress, and palpitations in 12%,
23%, and 88% respectively. Myocardial edema was detected in 54% of patients, and of these
patients, 50% were diagnosed with small pericardial effusions. While left ventricular ejection
fraction (LVEF) was within normal limits in 96.2% of patients, right ventricular (RV) function
was impaired due to sustained increased pulmonary vascular resistance. Significant differences
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in RV ejection fraction, stroke volume, stroke volume index, cardiac output, and cardiac index of
patients with positive CMR findings existed when compared to the control group.
Another CMR study revealed similar findings of patients who recovered from COVID19. Puntmann et al performed CMR exams an average of 71 days after positive COVID-19
results in 100 patients.25 Cardiac involvement was detected in 78% of participants. Cardiac
symptoms reported by patients included chest pain and palpitations 17% and 20% respectively.
Compared to the control group, the recovered COVID-19 patients had decreased LVEF, RV
ejection fraction, and increased LV volume. The most frequent anomaly was myocardial
inflammation, which was identified in 60% of patients who recovered from COVID-19.
Cardiovascular system changes after Covid-19 infection can also be seen on an
electrocardiogram (ECG). Eiros et al assessed ECGs of 139 participants approximately 10 weeks
after COVID-19 symptoms began.26 Electrocardiogram abnormalities included bundle branch
block, intraventricular conduction delay, ST-segment depression or T-wave inversion, STsegment elevation, and PR-segment depression in 6%, 11%, 16%, 9%, and 24% respectively.
Echocardiographic measures have also been implicated in post COVID-19 syndrome.
Fayol and colleagues conducted echocardiogram evaluations of patients 6 months after
diagnosis.27 At rest, echocardiographic values were normal for all patients, however, patients
with myocardial injury secondary to COVID-19 infection experienced LV diastolic markers such
as higher E/e’ ratios and increased pulmonary artery pressure resulting in pulmonary
hypertension in 27% of patients when performing low-level exercise.
Laboratory values such as troponin, C-reactive protein (CRP), and b-type natriuretic
peptide (BNP) have historically been used as cardiac associated inflammatory biomarkers. After
approximately 71 days, elevated troponins levels occurred 71% of the time in patients recovered
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from COVID-19, indicating inflammation and myocardial damage.25 However, other studies
performed 3-6 months after COVID-19 indicated no significant increases in cardiac
biomarkers.19,24
Nervous System
COVID-19 infection affects the central nervous system (CNS) in several ways including
persistent neuroinflammation, prolonged ICU and mechanical ventilation requiring sedation
medication, sepsis, and hippocampal atrophy.28 The most frequently reported CNS symptoms
reported by COVID-19 survivors included headache, memory loss, sleep disturbance, loss of
taste or smell, and musculoskeletal weakness.9,18,21,29,30 Three months after symptom onset, 55%
of patients still report these neurological manifestations.31 While these symptoms may be vague,
there have also been several case reports of Guillain-Barre syndrome, status epilepticus, and
cerebrovascular accidents.29 Cerebrovascular accidents have been reported to occur in 1.4% of
COVID-19 survivors and are mostly of ischemic origin. Incidences of Guillain-Barre syndrome
mostly occurred in the acute phase of COVID-19 infection, however, the disease led to decreased
muscle strength, prolonging recovery time. The presence of seizure activity secondary to
COVID-19 is attributed to viral infection of the CNS as well as acute hypoxic brain injury from
severe pneumonia.
Neurological changes associated with acute COVID-19 infection have been well
documented, however, post COVID-19 syndrome neurological sequela is limited due to the
infancy of the viral infection. Lu and colleagues performed MRI scans on COVID-19 patients 3
months after symptom onset.31 Patients were found to have a significantly higher amount of
bilateral gray matter volume in olfactory, hippocampi, insulas, left Rolandic operculum, left
Heschl’s gyrus, and right cingulate gyrus. Patients exhibited a decrease of mean, axial, and radial
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diffusivity, and an increase of fractional anisotropy in white matter. These imaging results
correlate with loss of memory and smell. Other MRI studies with similar time frames from
infection reported changes in the thalamus, posterior thalamic radiations, and sagittal stratum.19
Renal
The renal system has also been shown to be affected by COVID-19 infection due to the
virus’ high affinity for the Angiotensin-converting enzyme 2, which is heavily present in the
proximal tubules of the kidney, leading to cytotoxicity and inflammation.18 Researchers reported
a decrease in estimated glomerular filtration rate (eGFR) in 13% of patients 6 months after
diagnosis. These patients did not suffer acute kidney injury when admitted with COVID-19 and
were discharged with normal eGFR levels. Other studies indicated 3% of patients who
experienced acute kidney injury secondary to the viral infection continued to have renal
impairment 3 months after discharge.19 While Raman et al revealed no significant difference in
eGFR values, evidence of renal injury and inflammation was present in 29% of patients.
Gastrointestinal and Liver
Gastrointestinal (GI) symptoms are frequently reported as a long-term sequela after
COVID-19 infection. Among patients surveyed after 6 weeks from symptom onset, 34.6%
reported experiencing GI symptoms including nausea, diarrhea, abdominal pain, and anorexia.32
Similarly, 12 weeks after symptoms, more than 13% of patients continued to report GI
symptoms.21 Liver dysfunction after COVID-19 infection is rare. However, MRI results 2-3
months after the viral infection indicated signs of hepatic fibro-inflammation in 10% of
patients.19 Despite these imaging results, no other significant differences were reported in
patients who had recovered from COVID-19 when compared to the control group. Korompoki et
al recommend post COVID-19 infection follow up care to include assessment of liver function
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tests and abdominal imaging in some patients as these long-term GI symptoms can lead to
dyspepsia and irritable bowel syndrome.28
Endocrine
Limited research exists related to long-term sequela of COVID-19 infection and
endocrine pathologies. Given the pandemic is an ongoing problem, researchers recommend
extrapolating information from the previous outbreak of severe acute respiratory syndrome
(SARS) in 2003.33 Endocrine changes observed secondary to SARS infection included adrenal
insufficiency, hypocortisolism, and hypothyroidism.
As research is published, some endocrine function similarities between SARS and
COVID-19 have been reported. Chen et al examined thyroid function of COVID-19 patients 3
months after diagnosis and found 64% of patients had abnormal thyroid function laboratory
values.34 Majority of these patients had decreased thyroid stimulating hormone (TSH) and
triiodothyronine (T3) levels. A positive correlation existed between the decrease in TSH and T3
and the severity of COVID-19. These thyroid function laboratory values returned to normal
levels 3 months after recovery.
Other endocrine laboratory values have been linked to COVID-19 recovery as a result of
hospitalization and home-isolation. Eight weeks after onset of COVID-19, vitamin D deficiency
and insufficiency were present in 12% and 41% respectively for patients recovering at home and
38%, 27% during hospitalization.35, Parathyroid hormone was increased in 13% of patients.
These laboratory values did not correlate to the persistence of symptoms but remained
throughout the recovery period.
Diabetes mellitus (DM) has been strongly identified to increase morbidity and mortality
of COVID-19 infection, but effects on DM after infection are limited.28 COVID-19 infection
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causes inflammation within the pancreas leading to pancreatic beta-cell damage, insulin
resistance, and hyperglycemia. Medications such as antivirals and steroids used to treat the
infection have been known to cause hyperglycemia.28,33 Huang et al reported 3% of patients were
newly diagnosed with DM 6 months after COVID-19 infection.18
Mental health
While research on COVID-19 survivors is heavily focused on the physiological sequela,
significant changes in mental health cannot go unnoticed. Psychological sequela of COVID-19
infection results from elevated cytokines, social isolation, the experience of a potentially fatal
illness, stigma, and fear of infecting others.36 Approximately 1 month after infection, patients
self-reported mental health disorders including post-traumatic stress disorder (PTSD),
depression, anxiety, insomnia, and obsessive-compulsive behavior 28%, 31%, 42%, 40%, 20%
respectively. Among these patients, females were significantly more likely to report feelings of
anxiety and depression. Comparably, the diagnosis of anxiety (12.8%) and mood (9.9%)
disorders were described in patients during the first 14-90 days following the diagnosis of
COVID-19. 37 A self-report survey indicated COVID-19 survivors experienced a significantly
higher frequency of depression, anxiety, and reduced quality of life 3 months after diagnosis.19
Huang et al reported in a 6 month follow up study that 23% of patients reported anxiety or
depression, signifying these as more long-term mental health sequela from COVID-19
infection.18
While not specific to post COVID-19 survivors, an increase in substance abuse
throughout the general public has been recorded throughout the pandemic. Adult alcohol
consumption increased 14% from 2019 to 2020.38 Significant increases occurred among women,
younger adults, and non-Hispanic white populations. Increased alcohol consumption may
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exacerbate mental health problems, including anxiety and depression, which are present in
patients recovered from COVID-19 infection.
Anesthesia Implications
As millions of people have recovered from COVID-19 infection, patients are now
presenting for surgery with a history of COVID-19. As previously described, those who have
recovered from COVID-19 may have lasting sequela that may affect several different biological
processes. The development of post COVID-19 syndrome may have substantial implications for
anesthesia providers throughout the perioperative period. Published data is limited on the
management of anesthesia for previously infected patients. Therefore, it is imperative anesthesia
providers understand the potential residual effects of COVID-19 infection.
Given the lack of evidence of anesthetic care throughout the perioperative period for post
COVID-19 syndrome, anesthesia practice varies by provider. These fluctuations were evident in
a survey conducted of 154 anesthesiologists regarding alterations to preoperative evaluation of
COVID-19 recovered patients.39 Within the survey, the majority of anesthesiologists believed 02 weeks after a negative COVID-19 test was the ideal timing for elective surgeries. The majority
of these responders agreed the preoperative evaluation should include chest X-ray, EKG, and
coagulation laboratory values. Preoperative evaluation of asymptomatic patients included chest
CT, PFTs, and echocardiograms for those surveyed 24%, 18.8%, and 23.4% respectively. The
occurrence of preoperative testing increased based on the severity of COVID-19 infection.
Preoperative evaluation recommendations by the Indian Society of Anaesthesiologist
(ISA) include a complete blood count, coagulation profile, EKG, and electrolytes for every
patient with a history of COVID-19.40 Additional preoperative testing included chest X-ray for
major procedures and symptomatic American Society of Anesthesiologist Physical Status
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(ASAPS) II or higher. Chest CT, PFTs, arterial blood gases, and echocardiograms, were only
recommended for patients of moderate/severe hypoxia, presence of cardiac symptoms, geriatric,
or major abdominal, thoracic, cardiac, or vascular surgery.
Timing of elective procedures is an important factor when considering risks of
postoperative complications in patients after COVID-19 infection. El-Boghdadly et al express an
increased morbidity and mortality associated with surgery within 7 weeks of COVID-19
infection.10 The research recommends elective surgery should be delayed at least 7 weeks after
diagnosis unless postponing the procedure leads to disease progression. Meanwhile, the ASA and
APSF utilize a symptom-based stratification for the timing of elective procedures after recovery
from COVID-19.7 Within the ASA and APSF joint statement, a delay in elective procedures is
recommended in asymptomatic, symptomatic, hospitalized, or admitted to intensive care units
for 4, 6, 8-10, or 12 weeks respectively. The ASA and ASPF acknowledge these timeframes are
not definitive, and each patient should be assessed individually to determine perioperative risks.
Comparably, Oregon Health and Science University recently published a protocol for elective
surgery of previously COVID-19 positive patients.2 Within this protocol, patients must have a
resolution of symptoms and a minimum recovery time of 4 weeks for asymptomatic and 6-8
weeks for symptomatic patients. Similar results were produced by Kovoor et al, who
recommended a delay of at least 4 weeks for minor surgery and 8-12 weeks for major surgery.41
The optimal choice of anesthetic for patients exhibiting symptoms of post COVID-19
sequela has yet to be determined. Hoyler et al suggest if a patient presents with neurological
symptoms such as neuropathy, loss of taste, or loss of smell, the anesthesia provider should apply
anesthetic techniques similar to other neuromuscular disorders.15 Cautious administration of
opioid and neuromuscular blockers, as well as avoidance of regional anesthesia. Contrary to
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Hoyler et al., the ISA advocates for the use of regional anesthesia over general anesthesia if
possible given the decreased pulmonary reserves detected in post COVID-19 syndrome.40 Other
researchers state there is no evidence to support a superior anesthetic technique as there has been
no difference in postoperative complications.10 However, if general anesthesia is administered,
the ISA recommends the use of propofol or etomidate as induction agents, and neuromuscular
blockade be accomplished with the administration of cisatracurium, atracurium, vecuronium,
rocuronium, or succinylcholine.40
Discussion
Millions of people worldwide have been diagnosed with the novel COVID-19 viral
infection. Patients diagnosed with COVID-19 experience a variety of symptoms involving
multiorgan systems such as respiratory compromise, cardiomyopathy, renal dysfunction, and
neurological changes.2 Residual effects of COVID-19 have been observed up to 6 months after
diagnosis and are referred to as post COVID-19 syndrome.18,19,24,27 The physiological sequela of
post COVID-19 syndrome can have significant effects on PFTs, cardiac function, EKG and
echocardiogram changes, neurological, renal, GI, and endocrine function. Mental health is also
of concern as patients experienced increased levels of anxiety, depression, and PTSD.18,19,36,37
When patients with a history of COVID-19 infection present for surgical services, it is
imperative to consider the long-term effects of the infection and how patient outcomes may be
affected.
Vital for surgical services is the need for anesthesia care. Therefore, anesthesia providers
need to understand post COVID-19 syndrome sequela and associated anesthesia implications.
Data is limited in the recommended anesthetic management of these patients, so a thorough
preoperative assessment should be performed as symptoms vary on an individual basis.
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Preoperative evaluation varies widely as evidenced by surveyed anesthesiologists and the ISA’s
recommendations.39,40 A common theme appears to be delaying elective surgery until at least 4
weeks if not longer.2,7,10,41 There is conflicting evidence regarding anesthetic technique when
considering regional or general anesthesia, so the anesthesia provider must consider possible
sequela of previous COVID-19 infection when selecting the most appropriate anesthetic.10,15,40
Conclusion
The severity of post COVID-19 sequela differs significantly between patients and
evidence of residual effects of the viral infection are still not fully understood. As more people
recover from COVID-19 and variants of the virus develop, more patients are presenting for
surgical procedures with a history of COVID-19 infection. Guidance for the anesthetic
management of these patients is limited, so it is crucial for anesthesia providers to understand
post COVID-19 syndrome and associated symptoms.
This literature review explored residual symptoms after COVID-19 infection, which most
significantly related to the cardiopulmonary system, as well as other organ systems including
neurological, renal, GI, endocrine, and mental health. This literature review’s goal was to define
sequela associated with previous infection and discuss anesthetic implications for these patients.
The information obtained in this literature review establishes a foundation for a quality
improvement (QI) project to educate anesthesia providers on post COVID-19 syndrome
associated symptoms and anesthetic implications. By providing education to anesthesia providers
using the most recent evidence-based research, the QI project is expected to improve anesthesia
providers’ knowledge of the management for patients with post COVID-syndrome.
Primary DNP Project Goal
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The World Health Organization (WHO) declared Coronavirus 2019 a global pandemic on
March 11, 2020.8 Since then, several million have been infected worldwide. Approximately half
of those diagnosed with COVID-19 experienced what is known as post COVID-19 syndrome,
or symptoms affecting multiorgan systems that may remain for several months.2 Post COVID19 syndrome sequelae include but are not limited to fatigue, inflammation, chest tightness,
dyspnea, and headaches several months after diagnosis.
Many healthcare systems initially ceased elective procedures at the beginning of the
pandemic but have since resumed elective surgeries.3 As healthcare facilities resume surgical
procedures, patients are presenting with a medical history of COVID-19 infection. It is
estimated that 15% to 20% of patients requiring surgery have previously been infected with
COVID-19.10 Little is known about post COVID-19 syndrome and the anesthetic implications
of patients recovered from COVID-19 infection. Therefore, it is thought that an educational
presentation on the anesthetic management of patients with post COVID-19 syndrome will
improve anesthesia provider knowledge of the anesthetic management for patients who have
post COVID-19 syndrome.
At a large, level 1 trauma center in southeast Florida, the current process for elective
procedures of patients with a history of COVID-19 infection includes a minimum 3-week time
period after a positive test. The patient must also be considered asymptomatic, defined as
afebrile and absence of cough or shortness of breath. There is no preferred anesthetic technique
or preoperative testing, and the anesthetic plan of care is considered on an individual basis.
The primary goal of this quality improvement project is to assess the anesthesia
provider’s knowledge on post COVID-19 syndrome and associated anesthetic implications. An
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educational intervention will be delivered to anesthesia providers with the goal to improve
clinician knowledge as evidenced by a pre- and post-educational presentation survey. The
objective of this quality improvement project is to increase awareness of post COVID-19
syndrome sequelae and improve patient outcomes for elective procedures after COVID-19
infection.
Goals and Outcomes
Direction of the goals and objectives were derived from the SMART template.42 The
SMART acronym is a frequently used template to create goals and objectives that are specific,
measurable, attainable, realistic, and timely.
Specific
After an educational presentation, anesthesia providers will demonstrate improved
knowledge of anesthetic management for patients with post COVID-19 syndrome.
Measurable
The efficacy of the educational presentation will be analyzed by a questionnaire
completed by participants before and after an educational intervention. Results will be quantified
by measuring anesthesia providers’ knowledge of post COVID-19 sequelae and anesthetic
implications pre- and post-educational intervention. Qualtrics® software will be implemented to
create and analyze the results of the pre and post questionnaire.

Attainable
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Anesthesia providers, project team leader, and faculty from Florida International
University will collaborate using current evidence-based research to develop the educational
presentation.
Realistic
Anesthesia providers will be educated on post COVID-19 syndrome sequela and
associated anesthetic implications.
Timely
The pre-educational intervention questionnaire will be distributed among anesthesia
providers prior to the educational presentation and a post-intervention questionnaire delivered
immediately following the presentation. Results will be collected within a two-week time frame.
The outcome objective will be as follows: after an educational presentation, anesthesia providers
will improve knowledge of anesthetic management for patients who have post COVID-19
syndrome.
Description of the Program Structure
In collaboration with Florida International University faculty and an anesthesia provider,
the project leader will develop the educational presentation on post COVID-19 syndrome and
anesthetic implications. A detailed needs assessment will be executed using a SWOT analysis.42
A SWOT analysis discerns strengths of the project, address weaknesses, opportunities, and
acknowledges threats.
Identification of individuals, groups, or organizations who have vested interest in the
project are known as stakeholders.42 Internal stakeholders include anesthesia providers, project
teams members, surgeons, and patients. External stakeholders include people in the community,
anesthesia organizations, and insurers. Project team members will develop the educational
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intervention on post COVID-19 syndrome and associated anesthetic implications. Participants
will first be provided with a pre-educational intervention questionnaire consisting of 10 questions
to assess anesthesia providers’ current knowledge of post COVID-19 syndrome and anesthetic
implications. Participants will then be provided with an educational presentation on post
COVID-19 sequelae and associated anesthetic implications. The presentation will be provided to
anesthesia providers through email. After the educational presentation, participants will take a
post-presentation questionnaire.
Strengths
More evidence-based research is being produced on post COVID-19 syndrome sequelae
and the associated anesthetic management. One strength of the project is that the healthcare
organization has resumed elective procedures after initially stopping them during the pandemic.
Another strength is the project supports the healthcare facility’s vision, to provide research and
innovation for the benefit of the community. Evidence-based research is provided to the
anesthesia providers in the educational presentation. The objective of the project, to improve
anesthesia providers’ knowledge on post COVID-19 syndrome, is aligned with the vision of the
organization of interest.
Weaknesses
Weaknesses are areas for improvement within the project.42 One major weakness is the
development of COVID-19 infection, recovery, and variation. Several factors of the disease are
yet to be understood as the infection is relatively new. As Korompoki et al describe, mutations of
the virus may carry different risks or may vary in severity of illness when compared to what is
now known of the disease.28 As the fluidity of COVID-19 infection changes, so too might the
post COVID-19 syndrome sequelae and anesthetic management. Another weakness is that
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current evidence-based research available has several limitations such as low sample sizes,
which lowers the level of evidence. An anesthesia provider’s previous experience with patients
who have recovered from COVID-19 infection is also identified as a weakness. A provider’s
current knowledge of the disease and previous experience in administering anesthesia to patients
recovered from COVID-19 can lead to varying practice.39 This preconceived knowledge may
create disbelief of evidence provided in the education presentation.
Opportunities
Opportunities are derived from the assessment of strengths and weaknesses.42 The
educational presentation can be used for other healthcare facilities or anesthesia groups providing
surgical services to patients who have recovered from COVID-19 infection. Implementation of
the project within other organizations would improve provider knowledge of anesthesia for
patients with COVID-19 syndrome. Elimination of any weaknesses would not create additional
opportunities as COVID-19 infection continues to be an evolving situation.
Threats
Threats are barriers to the project, business, or organization that can impede outcomes.42
One threat is the recommendations from several different organizations involved. For example,
professional organizations such as the ASA or AANA may provide guidance on the anesthetic
management of patients with post COVID-19 syndrome, which may differ from what is
presented in the educational presentation. These recommendations could alter the anesthesia
provider’s pre- or post-intervention questionnaire answers.
Other threats include the existing policies and procedures for surgical services for
patients who have a history of COVID-19. Both the healthcare facility and anesthesia group
publish webinars or information related to the novel COVID-19 virus. Information that is
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accessible to the participants from other sources could negatively impact the project. Additional
unforeseen threats include the potential for societal or political regulations. Further lockdowns
enforced by the governments, or an increase of infection rates could cause another cessation of
elective procedures.

Strengths

Weakness

-Resumed elective
procedures
-Supports the facility’s
vision

-Viral variation
-Previous
expeirnce/knowledge

SWOT
Opportunities
-Other Healthcare facilities
-Other anesthesia groups

Threats
- Professional organizations
-Existing policies and
procedures
-Unforseen regulations

Methodology
Setting and Participants
Proper implementation of this quality improvement project requires a particular group of
study participants to receive an educational presentation on anesthetic implications of post
COVID-19 syndrome. The main setting of this quality improvement project will take place at a
large, level 1 trauma center in southeast Florida. Primary participants include all anesthesia
providers employed at this facility. The participants will be recruited voluntarily, and the
anticipated sample size will be between 5-15 participants.
The principal methodology of the proposed project is to administer an online educational
presentation to anesthesia providers encompassing the anesthetic implications of post COVID-19
syndrome. Participants will first complete an online pre-intervention test, evaluating current
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knowledge of post COVID-19 syndrome sequelae. Participants will then be given a 10 minute
online educational presentation on post COVID-19 syndrome and related anesthetic implications.
Participants will then be evaluated on knowledge gained as evidenced by a post-intervention test.
Results obtained in the post-intervention test will provide feedback regarding the impact
of the educational presentation. The pre/post-testing provides relevant information regarding the
efficacy of the educational presentation and seeks to improve anesthetic care of patients who
have recovered from COVID-19. Outcomes will also demonstrate if additional anesthesia
provider education is needed.
Protection of Human Subjects
For this quality improvement project, the recruitment population will include anesthesia
providers at a large, level 1 trauma center in southeast Florida. This population is significant
because they deliver anesthesia care to patients who have recovered from COVID-19 infection.
Participant recruitment will be conducted via email invitation to all anesthesia providers at this
location. Participation will be voluntary with no penalty for withdrawing from the project. There
are no perceived risks to the study as it only requires the time spent by each participant in the
education intervention.
Data Collection
Data collection will include a pre- and post-test to determine the effects of the
educational intervention. Both assessments will be conducted using surveys consisting of
approximately 12 questions focusing on knowledge and practice using Qualtrics. The pre-test
will assess knowledge of post COVID-19 anesthetic implications, while the post-test survey will
determine if the participants gained knowledge from the intervention. The instrument reliability
and validity will be measured in accordance with the intervention provided and its effectiveness
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for the participants. The data collected will be confidential and no subject identifiers will be
recorded during any component of the study.
Data Management and Analysis Plan
The DNP student will be responsible for administering the pre-test, educational
intervention, and post-test. Results will be kept using Microsoft Excel software and only
accessible to the DNP student and FIU faculty members. This data will be stored on a password
protected computer, ensuring confidentiality. Pre- and post-test results will be recorded to
identify knowledge base before and after the educational intervention. Statistical analysis will be
performed to determine effectiveness of the educational presentation and its impact to the
anesthesia provider.
Results
Demographics
A total of 42 invitations were distributed via email to anesthesia providers to participate
in the pre- and post-test educational intervention. Nine participants consented to participate,
however 3 surveys were incomplete, resulting in 6 participants for the quality improvement
project. The demographics of those who participated are represented by the following: male (n =
2, 33.3%), female (n = 4, 66.7%), age in years 25-35 (n = 4, 66.7%), age 36-45 (n = 2, 33.3%),
Hispanic (n = 1, 16.7%), Caucasian (n = 4, 66.7%), African American (n =1, 16.7%). All
participants were certified registered nurse anesthesthetists (n = 6), with either a Master’s degree
(n = 1, 16.7%), or Doctorate (n = 5, 83.3%), and less than 5 years experience (n = 5, 83.3%) or 510 years experience (n = 1, 16.7%) as an anesthesia provider. The demographics of participants
surveyed are represented below.
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Consent to participate
Answer

%

Count

Consent to participate

100.00%

9

Withdraw from survey

0.00%

0

Total

100%

9

Gender
Answer

%

Count

Male

33.33%

2

Female

66.67%

4

Non-binary

0.00%

0

Prefer not to say

0.00%

0

Total

100%

6

Age in years
Answer

%

Count

25-35

66.67%

4

36-45

33.33%

2

46-55

0.00%

0

56-65

0.00%

0

>65

0.00%

0

Total

100%

6

Ethnicity
Answer

%

Count

Hispanic

16.67%

1

Caucasian (non-Hispanic)

66.67%

4

African American

16.67%

1

Asian

0.00%

0

Other

0.00%

0

Total

100%

6
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Position/Title
Answer

%

Count

Certified Registered Nurse Anesthetist

100.00%

6

MD anesthesia

0.00%

0

Total

100%

6

Highest level of education
Answer

%

Count

Associates

0.00%

0

Bachelors

0.00%

0

Masters

16.67%

1

Doctorate

83.33%

5

Other

0.00%

0

Total

100%

6

Years of practice as an anesthesia provider
Answer

%

Count

Less than 5

83.33%

5

5-10

16.67%

1

10-15

0.00%

0

Greater than 15

0.00%

0

Total

100%

6

Pre-Test Knowledge of post COVID-19 Anesthetic Implications
The pre-test consisted of 12 questions that assessed the current knowledge of post-COVID19 anesthesia implications. No participants correctly identified the American Society of
Anesthesiologist Physical Status (ASAPS) recommendation for preoperative chest radiographs.
Three participants (50%) selected ASAPS I, whereas ASAPS III and IV were selected by
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1(16.7%) and 2 (33.3%) participants respectively. Three (50%) participants correctly identified
the minimum recommended length of time for an elective procedure after COVID-19 infection.
The majority (n = 4, 66.7%) of those surveyed correctly identified the recommended induction
agent for patients with post-COVID-19 syndrome. However, only 1 participant correctly selected
the preferred neuromuscular blocker. Two (33.3%) participants were able to identify
recommended anesthetic techniques. Selection of the best volatile inhalational agent was evenly
split between Isoflurane (n=3) and Sevoflurane (n=3). Interestingly, all participants (n = 6)
correctly identified cardiac sequela of right ventricular dysfunction. However, only 1 participant
answered appropriate electrocardiogram (ECG) findings of PR depression. Half (n = 3) of the
participants incorrectly answered ST depression as the most frequent ECG finding. No
participants correctly identified which pulmonary function test was most frequently reduced.
All 6 participants answered “sometimes” to consider additional preoperative testing for
patients after previous COVID-19 infection. When questioned if their anesthetic plan changes for
patients with previous COVID-19 infection, 2 (33.3%) participants stated “sometimes” and 4
(66.7%) answered “never.” However, 5 (83.3%) participants responded “sometimes” and 1
responded “often” to considering previous COVID-19 infection when performing a preoperative
evaluation.
Post-Test Knowledge of post COVID-19 Anesthetic Implications
After the voiceover PowerPoint educational intervention, participants answered a postintervention questionnaire consisting of the same questions found in the pre-test. Results
assessed the knowledge gained from the educational intervention and are listed below (Table 1).
All questions demonstrated an increase in the correct answer when the pre- and post-intervention
tests were compared. Most significantly, the response to the selection of volatile agents. In the
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pre-test, 0 anesthesia providers selected the appropriate volatile anesthetic agent compared to 5
(83.3%) correctly identifying that any agent is acceptable in the post-intervention test. Another
dramatic increase in knowledge was correctly identifying preoperative chest X-ray
recommendations for ASAPS II after COVID-19 infection. Four respondents answered this
question correctly post-intervention, compared to 0 in the pre-intervention test. Both the
selection of pulmonary function test reduction and preferred neuromuscular blocker resulted in a
50% increase in the post-intervention questionnaire.
No difference was observed in the pre-and post-test with two questions. The first,
concerning right ventricular dysfunction. All participants answered this question correctly in
both the pre- and post-tests. The other question which resulted in no change was pertaining to
the timing of elective procedures.
When asked questions about the attitude toward the anesthetic management of recovering
COVID-19 patients, results varied. After the educational intervention, 50% of respondents stated
they would “always” (n = 1, 16.7%) or “often” (n = 2, 33.3%) consider additional pre-operative
testing compared to answering “sometimes” in the pre-intervention questions. There was a 75%
decrease in “never” changing an anesthetic plan with previously COVID-19 infected patients.
Lastly, there was an increase in “always” (n = 1, 16.7%) and “often” (n = 3, 50%) considering
previous COVID-19 infection during preoperative evaluation.
Table 1
Question

A preoperative chest X-ray is
recommended for which American
Society of Anesthesiologist Physical
Status (ASAPS) when a patient has a
history of COVID-19 infection?

Pre-Test

Post-Test

Difference

(n=6)

(n=6)

(%)

0

4

66.7
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After an asymptomatic COVID-19
infection, what is the recommended
length of time an elective procedure
should be performed?
What is the recommended induction
agent for patients with post COVID-19
syndrome?

3

3

0

4

5

16.7

What is the preferred neuromuscular
blocker for patients with COVID-19
syndrome?

1

4

50

What is the recommended anesthetic
technique for patients with post
COVID-19 syndrome?

2

4

33.3

Which cardiac sequela may exist
among patients who have had
previous COVID-19 infection?

6

6

0

What is the most frequently
associated electrocardiogram (ECG)
finding in patients after COVID-19
infection?

1

3

33.3

Which volatile inhalational agent is
the preferred inhalational gas when
delivered to a patient with a history of
COVID-19?

0

5

83.3

Six (6) months after COVID-19
infection, which pulmonary function
test is most frequently reduced (<80%
predicted)?

0

3

50

Summary of Data
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Overall, the results of the educational intervention demonstrated an increase in knowledge
between the pre-test and post-tests, except for right ventricular dysfunction and the timing of
elective procedures after infection. The most significant increase in knowledge was observed by
correctly identifying minimum ASAPS for chest X-ray, and for volatile agent selection. The
graphs below illustrate the difference between the pre- and post-test answers for each question.

A preoperative chest X-ray is recommended for
which American Society of Anesthesiologist Physical
Status (ASAPS) when a patient has a history of
COVID-19 infection?
6
4
2
0
I

II

III

Pre-Test

IV

Post-Test

After an asymptomatic COVID-19 infection, what is
the recommended length of time an elective
procedure should be performed?
3.5
3
2.5
2
1.5
1
0.5
0
2 Weeks

4 Weeks
Pre-Test

6 Weeks
Post-Test
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What is the recommended induction agent for
patients with post COVID-19 syndrome?
6
5
4
3
2
1
0
High dose opioid
induction

ketamine
Pre-Test

Inhalational

Propofol or
Etomidate

Post-Test

What is the preferred neuromuscular blocker for
patients with COVID-19 syndrome?
4.5
4
3.5
3
2.5
2
1.5
1
0.5
0
There is no superior
neuromuscular
blocker

Cisatracurium

Pre-Test

Rocuronium

Post-Test
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What is the recommended anesthetic technique for
patients with post COVID-19 syndrome?
4.5
4
3.5
3
2.5
2
1.5
1
0.5
0
General anesthesia Regional anesthesia
with an
endotracheal tube
Pre-Test

Monitored
anesthesia care
(MAC)

There is no superior
anesthesetic
technique

Post-Test

Which cardiac sequela may exist among patients
who have had previous COVID-19 infection?
7
6
5
4
3
2
1
0
Left ventricuar
dysfunction

Right ventricular
dysfunction
Pre-Test

Atrial enlargement
Post-Test
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What is the most frequently associated
electrocardiogram (ECG) finding in patients after
COVID-19 infection?
3.5
3
2.5
2
1.5
1
0.5
0
ST depression

T wave inversion
Pre-Test

Bundle branch block

PR depression

Post-Test

Which volatile inhalational agent is the preferred
inhalational gas when delivered to a patient with a
history of COVID-19?
6
5
4
3
2
1
0
Isoflurane

Sevoflurane
Pre-Test

Desflurane
Post-Test
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Six (6) months after COVID-19 infection, which
pulmonary function test is most frequently reduced?
4.5
4
3.5
3
2.5
2
1.5
1
0.5
0
Forced vital capacity Forced expiratory
Total lung capacity
(FVC)
volume in one second
(FEV1)
Pre-Test

Residual volume

Post-Test

How often do you consider additional preoperative
testing when a patient presents for an elective
procedure after previous COVID-19 infection?
7
6
5
4
3
2
1
0
Always

Often
Pre-Test

Sometimes
Post-Test
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How frequent do you change your anesthetic plan when
your patient has had a previous COVID-19 infection?
4.5
4
3.5
3
2.5
2
1.5
1
0.5
0
Always

Often
Pre-Test

Sometimes

Never

Post-Test

How often do you consider previous COVID-19
infection when performing preoperative evaluation?
6
5
4
3
2
1
0
Always

Often

Sometimes

Pre-Test

Never

Post-Test

Discussion
Limitations
This quality improvement project had several limitations including small sample size.
Forty-two surveys were distributed via email to anesthesia providers at one location, however
only 6 participants completed the pre-test, educational intervention, and post-test in its entirety.
A larger, more diverse sample size would allow for a more accurate representation of the
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preexisting knowledge of the anesthetic management for patients recovered from COVID-19
infection. Additionally, a larger sample size would validate the efficacy of the educational
intervention. Another limitation is the time frame. Participants were allowed two weeks to
complete the survey. Additional time may have allowed for an increased response rate. Lastly, it
is recognized that this quality improvement project only took place at one facility. If distributed
to other locations, results would more accurately reflect anesthesia providers, instead of just one
community.
Future Implications for Advanced Nursing Practice
The novel Coronavirus 2019 has infected millions of patients worldwide and at one point
was declared a global pandemic. Despite the new research, more patient awareness, and access to
vaccinations, the virus continues to spread. Several new variants have developed since the
publication of the research articles used in this quality improvement project, and more are likely
to come. Residual effects of COVID-19 can be observed several months after diagnosis,
affecting multisystem physiological processes. These post-COVID-19 sequela can alter the
anesthetic management of these patients. As healthcare workers continue to care for patients who
present with a history of COVID-19 infection, it is vital for anesthesia providers to understand
possible implications as it relates to anesthetic management. As new variants of the infection
continue to emerge, new guidelines will be provided. For example, the ASA and APSF joint
statement was updated on June 15, 2022.43 Within this statement, the organization recommends
screening for COVID prior to presenting to healthcare facilities and canceling elective surgery
for positive test results. Staying informed with current research is necessary and more research
will need to be conducted to provide safe, quality care to patients.
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Conclusion
As the COVID-19 virus continues to evolve, more patients are presenting for surgery
with a history of COVID-19 infection. Recovery can vary patient to patient, but can have
significant sequela related to post COVID-19 syndrome. Without the knowledge of associated
sequela of post COVID-19 syndrome and related anesthesia implications, anesthesia providers
may not be able to provide the best quality care for these patients. Therefore, it would be prudent
for the anesthesia provider to take into consideration the patient’s history of COVID-19
infection. Educational interventions such as this quality improvement project can effectively
increase provider knowledge and the likelihood of utilizing current evidence-based research to
provide safe, quality care and improve overall patient outcomes.
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Appendix B: QI Project Consent

CONSENT TO PARTICIPATE IN A QUALITY IMPROVEMENT PROJECT
“Anesthetic Management of Patients with Post COVID-19 Syndrome”

SUMMARY INFORMATION
Things you should know about this study:








Purpose: Educational module concerning the anesthetic management of patients who
have recovered from COVID-19 infection.
Procedures: Participate in a pre-test, view an Educational Module via voice over
PowerPoint, then participate in a post test
Duration: This will take about a total of 20 minutes.
Risks: The main risk or discomfort from this research is minimal
Benefits: The main benefit to you from this research is increase the participant’s
knowledge on perioperative management of patients recovered from COVID-19 and
anesthetic implications.
Alternatives: There are no known alternatives available to you other than not taking
part in this study.
Participation: Taking part in this research project is voluntary.

Please carefully read the entire document before agreeing to participate.

PURPOSE OF THE PROJECT

The goal of this project is to improve health care provider knowledge on anesthetic
implications throughout the perioperative period for patients who have recovered from
COVID-19. You are being asked to participate in this quality improvement project

DURATION OF THE PROJECT
Your participation will require about 20 minutes of your time, you will be one of 10 people in
this study
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PROCEDURES
If you agree to be in the project, we will ask you to do the following things: Participate in a
pretest view, an Educational Module via voice over PowerPoint, then participate in a post test.

RISKS AND/OR DISCOMFORTS
Minimal risk, risk not greater than if participant was conducting similar activity. Physical,
psychological, social, legal, and economic risks minimal and no greater than if a participant was
participating in a similar activity. Similar activity such as filling out an online survey and
watching voice over PowerPoint.

BENEFITS
The following benefits with your participation in this project: An increase in your knowledge
of post COVID-19 syndrome and related anesthetic implications throughout the perioperative
period.

ALTERNATIVES
There are no known alternatives available to you other than not taking part in this project.
However, if you would like to receive the educational material given to the participants in this
project, it will be provided to you at no cost.

CONFIDENTIALITY
The records of this project will be kept private and will be protected to the fullest extent
provided by law. If, in any sort of report, we might publish, we will not include any
information that will make it possible to identify you as a participant. Records will be stored
securely, and only the project team will have access to the records.

PARTICIPATION: Taking part in this research project is voluntary.

COMPENSATION & COSTS
There is no cost or payment to you for receiving the health education and/or for participating in
this project.

RIGHT TO DECLINE OR WITHDRAW
Your participation in this project is voluntary. You are free to participate in the project or
withdraw your consent at any time during the project. Your withdrawal or lack of participation
will not affect any benefits to which you are otherwise entitled. The investigator reserves the
right to remove you without your consent at such time that they feel it is in the best interest.

RESEARCHER CONTACT INFORMATION
If you have any questions about the purpose, procedures, or any other issues relating to this
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research project, you may contact Joseph Benson at 630-636-1720, Jbens031@fiu.eduj or Dr.
Jorge Valdes at 305-348-7729/jvalde@fiu.edu.

IRB CONTACT INFORMATION
If you would like to talk with someone about your rights pertaining to being a subject in this
project or about ethical issues with this project, you may contact the FIU Office of Research
Integrity by phone at 305-348-2494 or by email at ori@fiu.edu.

PARTICIPANT AGREEMENT
I have read the information in this consent form and agree to participate in this study. I have had
a chance to ask any questions I have about this study, and they have been answered for me. By
clicking on the “consent to participate” button below I am providing my informed consent.
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Appendix E: Pretest and Posttest Questionnaire

Pretest and Posttest Questionnaire:
Anesthetic Management of Patients with Post COVID-19 Syndrome
INTRODUCTION
The primary aim of this QI project is to improve the knowledge of on anesthetic
implications throughout the perioperative period for patients who have recovered from COVID19.
Please answer the question below to the best of your ability. The questions are either in
multiple choice or true/false format. These questions are meant to measure knowledge and
perceptions on identification, referral, management, and patient education on patients recovered
from post COVID-19.
PERSONAL INFORMATION
1. Gender
a. Male
b. Female
c. Non-binary
d. Prefer not to answer
2. Age in years
a. 25-35
b. 36-45
c. 46-55
d. 56-65
e. > 65
3. Ethnicity:
a. Hispanic
b. Caucasian (non-Hispanic)
c. African American
d. Asian
e. Other
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4. Position/Title
a. Certified Registered Nurse Anesthetist
b. MD anesthesia
5. Highest level of education
a. Associates
b. Bachelors
c. Masters
d. Doctorate
e. Other
6. Years of practice as an anesthesia provider
a. Less than 5
b. 5-10
c. 10-15
d. Greater than
QUESTIONNAIRE
A preoperative chest X-ray is recommended for which American Society of Anesthesiologist
Physical Status (ASAPS) when a patient has a history of COVID-19 infection?
e. I
f. II
g. III
h. IV or higher
1. After an asymptomatic COVID-19 infection, what is the recommended length of time an
elective procedure should be performed?
a. 2 weeks
b. 4 weeks
c. 6 weeks
d. 8 weeks or greater
2. What is the recommended induction agent for patients with post COVID-19 syndrome?
a. High dose opioid induction
b. Ketamine
c. Inhalational
d. Propofol or Etomidate
3. What is the preferred neuromuscular blocker for patients with COVID-19 syndrome?
a. There is no superior neuromuscular blocker
b. Cisatracurium
c. Rocuronium
d. Vecuronium
4. What is the recommended anesthetic technique for patients with post COVID-19
syndrome?
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a.
b.
c.
d.

General anesthesia with an endotracheal tube
Regional anesthesia
Monitored anesthesia care (MAC)
There is no superior anesthetic technique

5. Which cardiac sequela may exist among patients who have had previous COVID-19
infection?
a. Left ventricular dysfunction
b. Right ventricular dysfunction
c. Atrial enlargement
d. Aortic stenosis
6. What is the most frequently associated electrocardiogram (ECG) finding in patients after
COVID-19 infection?
a. ST depression
b. T wave inversion
c. Bundle branch block
d. PR depression.
7. Which volatile inhalational agent is the preferred inhalational gas when delivered to a
patient with a history of COVID-19?
a. Isoflurane
b. Sevoflurane
c. Desflurane
d. All are acceptable volatile agents
8. Six (6) months after COVID-19 infection, which pulmonary function test is most
frequently reduced (<80% predicted)?
a. Forced vital capacity (FVC)
b. Forced expiratory volume in one second (FEV1)
c. Total lung capacity (TLC)
d. Residual volume (RV)
9. How often do you consider additional preoperative testing when a patient presents for an
elective procedure after previous COVID-19 infection?
a. Always
b. Often
c. Sometimes
d. Never
10. How frequent do you change your anesthetic plan when your patient has had a previous
COVID-19 infection?
a. Always
b. Often
c. Sometimes
d. Never
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11. How often do you to consider previous COVID-19 infection when performing
preoperative evaluation?
a. Always
b. Often
c. Sometimes
d. Never
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Appendix F: QI Educational Module
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Table 2. Overview of Literature Review Results
Authors
Frija-Masson et al.17
Zhao et al.13
Huang et al.18

Research Design
(Sample size)
Retrospective study
(n = 50)
Retrospective study
(n = 55)
Ambidirectional cohort
study
(n = 390)

Timing after
COVID-19
30 days after onset
3 moths after discharge
6 months

Raman et al.19

Observational
(n = 58)

2-3 months

Huang et al.24

Retrospective
observational study (n=
26)
Prospective Cohort
study
(n = 277)
Prospective
observational study
(n= 100)
Retrospective
(n = 112)

1-2 months

Moreno-Pérez et al.9
Puntmann et al.25
Ding et al.20
Eiros et al.26
Fayol et al.27

Observational cohort
study
(n=139)
Prospective cohort study
(n= 48)

77 days after disease
onset
71 days

Findings
>50% display abnormal lung function
Decreased PFTs
Abnormal radiologic results
Decreased PFTs
Abnormal CT results
Patients report chest pain (5%) and palpitations (9%) 6 months after diagnosis
patients report
Muscle weakness 63%
Headache 2%
Sleep difficulty 26%
Smell disorder 11%
13% of patients experience decreased GFR
Increased anxiety or depression
64% of patients reported breathlessness
60% showed MRI lung abnormalities
No increase in cardiac biomarkers
MRI changes in thalamus, posterior thalamic radiations, and sagittal stratum
29% of patients have renal inflammation
MRI shows hepatic fibro-inflammation in 10% of patients
Increased depression, anxiety, and reduced quality of life
Abnormal Cardiac magnetic resonance imaging evidenced as myocardial edema
Decreased PFTs
Radiological abnormalities
Headache, memory disorder or cognitive deterioration present in 11.9% of patients
78% of patients had cardiac involvement identified on Cardiac magnetic resonance

6 different stages after
onset
(0->28 days)
10 weeks

CT abnormalities rapidly evolved, and 98% remained at 28 days

6 months

Cardiac diastolic abnormalities observed on echocardiogram

Pericarditis and myocarditis present in asymptomatic patients
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Taylor et al.21

Online/telephone
questionnaire and follow
up chest X-ray (n = 675)

12 weeks after discharge

Chest X-ray showed resolution in 69% of high-risk patients and 83% of low-risk
patients
Difficulty reported in sleep, memory, concentration, musculoskeletal taste and smell
reported in 19-36% of patients
13% report GI symptoms

Korompoki et al. 28

Literature review

N/A

D'Cruz et al.22

Prospective
observational cohort
study (n = 119)
Non-systematic review

61 days

CNS and PNS effects may be related to prolonged ICU stay, sepsis, and medications.
Recommendation of Liver function test and abdominal imaging during evaluation
Long term effects on DM is limited, Covid treatment may cause hyperglycemia
Chest X-ray poor indication of recovery

Prospective study
(n= 143)
Prospective study
(n= 60)
Chart review
(n= 26)
Retrospective study
(n= 50)
Prospective,
observational study
(n= 109)
Prospective cohort study
(n = 402)
Electronic health record
cohort study
(n = 62 354)
Survey
(n = 15 40)
Cross sectional survey
(n= 154)
N/A

60 days after onset

Patient report headache on follow up survey

3 months

55% of patients showed neurological symptoms on MRI

Greater than 6 weeks

34.6% reported nausea, diarrhea, abdominal pain, and anorexia

3 months

64% of patients had abnormal thyroid function

8 weeks

Decreased vitamin D and increased PTH

30 days

Self-report of PTSD, depression, anxiety, and obsession compulsion

14-90 days

Covid-19 survivors are at increased risk of psychiatric sequela such as anxiety and
mood disorders

N/A

Increased alcohol consumption with onset of pandemic

N/A

Varied preoperative assessments

N/A

Recommended anesthesia management

N/A

Delay elective surgery >7 weeks

N/A

Four weeks for an asymptomatic patient or recovery from only mild, non-respiratory
symptoms.

Camargo-Martínez et al.

Case reports of Guillain-Barre syndrome, status epilepticus, and cerebrovascular
accidents

29

Carfì et al.30
Lu et al.31
Cellai et al.32
Chen et al.34
Pizzini et al.35
Mazza et al.36
Taquet et al.37
Pollard et al.38
Wajekar et al.39
Malhotra et al.40
(ISA advisory and
position statement)
El‐Boghdadly et al.10
American Society of
Anesthesiologists and

Multidisciplinary
consensus statement
Position statement
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Anesthesia Patient
Safety Foundation Joint
Statement 7

Bui et al.2
Kovoor et al.41
Hoyler et al.15

Preoperative evaluation
framework
Clinical expert advice
and grey literature
review
Letter to the editor

N/A
3-16 weeks

• Six weeks for a symptomatic patient (e.g., cough, dyspnea) who did not require
hospitalization.
• Eight to 10 weeks for a symptomatic patient who is diabetic, immunocompromised, or
hospitalized.
•Twelve weeks for a patient who was admitted to an intensive care unit due to COVID19 infection.
Delay in surgery 4 weeks for asymptomatic
6-8 weeks for symptomatic patients
Delay 4 weeks for minor surgery
8-12 weeks for major surgery

N/A

Perioperative considerations with post Covid-19 syndrome
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